Related Experiment Video
Updated: May 15, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
[Heart failure with preserved ejection fraction (diastolic heart failure)]
István Czuriga1, Attila Borbély, Dániel Czuriga
1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Kardiológiai Intézet Debrecen Móricz Zs. krt. 22. 4032. iczuriga@med.unideb.hu
Insights
Diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF), affects over half of heart failure patients. Current treatments focus on managing symptoms and comorbidities due to a lack of evidence-based therapies for HFpEF itself.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Diastolic heart failure (HFpEF) is a prevalent clinical syndrome characterized by heart failure symptoms with preserved left ventricular ejection fraction (≥ 50%).
- Epidemiological data indicate HFpEF constitutes over 50% of heart failure cases, disproportionately affecting older women and those with comorbidities like hypertension and diabetes.
- The pathophysiology of HFpEF is complex and heterogeneous, posing diagnostic and therapeutic challenges.
Purpose:
- This review aims to summarize current knowledge on diastolic heart failure, covering its epidemiology, pathophysiology, diagnosis, and management strategies.
- To highlight the diagnostic utility of echocardiography in identifying diastolic dysfunction.
- To discuss the current therapeutic landscape, emphasizing symptom management and addressing contributing comorbidities.
Summary:
- Diagnosis of HFpEF relies on echocardiography to detect diastolic dysfunction, including impaired myocardial relaxation and increased filling pressures, despite normal ejection fraction.
- Unlike heart failure with reduced ejection fraction, evidence-based treatments specifically for HFpEF are limited.
- Management strategies for HFpEF are primarily empirical, focusing on blood pressure normalization, heart rate control, symptom relief from congestion using diuretics, and treating underlying conditions like hypertension and diabetes.
Impact:
- This review provides a comprehensive overview of HFpEF, informing clinicians about the current understanding and management of this common condition.
- It underscores the need for further research to develop targeted, evidence-based therapies for HFpEF.
- Improved understanding and management of HFpEF can lead to better patient outcomes and reduced healthcare burden.
Abstract:
Diastolic heart failure, which is also called as heart failure with preserved ejection fraction, is a clinical syndrome in which patients have signs and symptoms of heart failure, normal or near normal left ventricular ejection fraction (≥ 50%) and evidence of diastolic dysfunction. Recent epidemiological studies have demonstrated that more than half of all heart failure patients have diastolic heart failure. The syndrome is more common in women than in men and the prevalence increases with age. Patients with diastolic heart failure form a fairly heterogeneous group with complex pathophysiologic mechanisms. The disease is often in association with other comorbidities, such as hypertension, diabetes mellitus or obesity. The diagnosis of diastolic heart failure is best achieved by two-dimensional and Doppler echocardiography, which can detect abnormal myocardial relaxation, decreased compliance and increased filling pressure in the setting of normal left ventricular dimensions and preserved ejection fraction. Unlike heart failure with reduced ejection fraction, there is no such an evidence-based treatment for heart failure with preserved ejection fraction, which would improve clinical outcomes. Thus, pharmacological therapy of diastolic heart failure is based mainly on empiric data, and aims to the normalization of blood pressure, reduction of left ventricular dimensions and increased heart rate, maintenance of normal atrial contraction and treatment of symptoms caused by congestion. Beneficial effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers may be utilized in patients with diastolic dysfunction, especially in those with hypertension. Beta-blockers appear to be useful in lowering heart rate and thereby prolonging left ventricular diastolic filling time, while diuretic therapy is the mainstay of treatment for preventing pulmonary congestion. Nonetheless, treatment of the underlying disease is also an important therapeutic approach. This review summarizes the state of current knowledge with regard to diastolic heart failure.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure I: Introduction
Heart Failure III: Clinical Manifestations
Heart Failure V: Medical Management
